Neurogene Inc. Files 8-K for Disclosure and Exhibits
Ticker: NGNE · Form: 8-K · Filed: Mar 4, 2024 · CIK: 1404644
Sentiment: neutral
Topics: disclosure, financial-statements, corporate-filing
TL;DR
Neurogene Inc. filed an 8-K on March 4, 2024, for disclosures and exhibits.
AI Summary
Neurogene Inc. filed an 8-K on March 4, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Neoleukin Therapeutics, Inc., is based in New York, NY.
Why It Matters
This filing provides important updates and financial information for investors and stakeholders of Neurogene Inc.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, indicating standard corporate reporting rather than a specific event with immediate high risk.
Key Players & Entities
- Neurogene Inc. (company) — Registrant
- Neoleukin Therapeutics, Inc. (company) — Former company name
- March 4, 2024 (date) — Date of report
- New York, NY (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing by Neurogene Inc.?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and Financial Statements and Exhibits.
When was this 8-K report filed?
This 8-K report was filed on March 4, 2024.
What was Neurogene Inc.'s former company name?
Neurogene Inc.'s former company name was Neoleukin Therapeutics, Inc.
Where are Neurogene Inc.'s principal executive offices located?
Neurogene Inc.'s principal executive offices are located at 535 W 24th Street, 5th Floor, New York, NY 10011.
What is Neurogene Inc.'s IRS Employer Identification Number?
Neurogene Inc.'s IRS Employer Identification Number is 98-0542593.
Filing Stats: 617 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2024-03-04 07:30:39
Key Financial Figures
- $0.000001 — nge on which registered Common Stock, $0.000001 par value NGNE The Nasdaq Global Ma
Filing Documents
- d754656d8k.htm (8-K) — 25KB
- d754656dex991.htm (EX-99.1) — 20KB
- d754656dex992.htm (EX-99.2) — 42KB
- g754656ex99_2p10g1.jpg (GRAPHIC) — 359KB
- g754656ex99_2p11g1.jpg (GRAPHIC) — 290KB
- g754656ex99_2p12g1.jpg (GRAPHIC) — 242KB
- g754656ex99_2p13g1.jpg (GRAPHIC) — 251KB
- g754656ex99_2p14g1.jpg (GRAPHIC) — 235KB
- g754656ex99_2p15g1.jpg (GRAPHIC) — 201KB
- g754656ex99_2p16g1.jpg (GRAPHIC) — 253KB
- g754656ex99_2p17g1.jpg (GRAPHIC) — 327KB
- g754656ex99_2p18g1.jpg (GRAPHIC) — 278KB
- g754656ex99_2p19g1.jpg (GRAPHIC) — 416KB
- g754656ex99_2p1g1.jpg (GRAPHIC) — 411KB
- g754656ex99_2p20g1.jpg (GRAPHIC) — 212KB
- g754656ex99_2p21g1.jpg (GRAPHIC) — 105KB
- g754656ex99_2p22g1.jpg (GRAPHIC) — 200KB
- g754656ex99_2p23g1.jpg (GRAPHIC) — 230KB
- g754656ex99_2p24g1.jpg (GRAPHIC) — 250KB
- g754656ex99_2p25g1.jpg (GRAPHIC) — 312KB
- g754656ex99_2p26g1.jpg (GRAPHIC) — 91KB
- g754656ex99_2p27g1.jpg (GRAPHIC) — 226KB
- g754656ex99_2p28g1.jpg (GRAPHIC) — 181KB
- g754656ex99_2p29g1.jpg (GRAPHIC) — 394KB
- g754656ex99_2p2g1.jpg (GRAPHIC) — 680KB
- g754656ex99_2p30g1.jpg (GRAPHIC) — 325KB
- g754656ex99_2p31g1.jpg (GRAPHIC) — 222KB
- g754656ex99_2p32g1.jpg (GRAPHIC) — 245KB
- g754656ex99_2p33g1.jpg (GRAPHIC) — 305KB
- g754656ex99_2p34g1.jpg (GRAPHIC) — 295KB
- g754656ex99_2p35g1.jpg (GRAPHIC) — 189KB
- g754656ex99_2p36g1.jpg (GRAPHIC) — 198KB
- g754656ex99_2p3g1.jpg (GRAPHIC) — 261KB
- g754656ex99_2p4g1.jpg (GRAPHIC) — 371KB
- g754656ex99_2p5g1.jpg (GRAPHIC) — 173KB
- g754656ex99_2p6g1.jpg (GRAPHIC) — 314KB
- g754656ex99_2p7g1.jpg (GRAPHIC) — 388KB
- g754656ex99_2p8g1.jpg (GRAPHIC) — 238KB
- g754656ex99_2p9g1.jpg (GRAPHIC) — 91KB
- 0001193125-24-056852.txt ( ) — 13674KB
- ngne-20240304.xsd (EX-101.SCH) — 3KB
- ngne-20240304_lab.xml (EX-101.LAB) — 18KB
- ngne-20240304_pre.xml (EX-101.PRE) — 11KB
- d754656d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated March 4, 2024 99.2 Corporate Presentation (March 2024) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NEUROGENE INC. Date: March 4, 2024 By: /s/ Christine Mikail Name: Christine Mikail Title: President and Chief Financial Officer